There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), Dyadic International (DYAI – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.
Anavex Life Sciences (AVXL)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences today and set a price target of $54.00. The company’s shares closed last Monday at $7.00.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Anavex Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $56.00, implying a 700.0% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $58.00 price target.
See the top stocks recommended by analysts >>
Dyadic International (DYAI)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Dyadic International today and set a price target of $6.00. The company’s shares closed last Monday at $1.81.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dyadic International with a $6.00 average price target.
Legend Biotech (LEGN)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Legend Biotech today and set a price target of $87.00. The company’s shares closed last Monday at $60.50.
According to TipRanks.com, Kapoor is ranked 0 out of 5 stars with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $90.01, implying a 40.6% upside from current levels. In a report issued on November 13, BMO Capital also maintained a Buy rating on the stock with a $90.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVXL:
- Anavex appoints David Goldberger as SVP, regulatory affairs
- Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
- Anavex reports new publication on potential of ANAVEX 3-71
- Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
